KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Lina Zhang, Jingxuan Wang, Tao Sun, Fanfan Li, Bing Zhao, Guohui Han, Zhongsheng Tong, Hua Yang, Yongmei Yin, Xiangshun Kong, Ying Wang, Jianyun Nie, Lixia Ma, Yongqiang Zhang, Jing Luo, Changping Shan, Jing Yao, Shisheng Tan, Xiaoling Ling, Hongmei Sun, Huihui Li, Li Ma, Tao Zhou, Yunjiang Liu, Yixin Qi, Zhenchuan Song, Yuntao Li, Chao Yang, Tianli Hui, Meiqi Wang, Haoqi Wang, Xi Zhang, Wenhui Zhao, Yanhui Li, Mengmeng Li, Ying Xin, Xuan Luo, Deliang Yin, Hongmei Luo, Huan Liu, Qianyun Lu, Jing Yuan, Qingyuan Zhang, Cuizhi Geng

Cancer Commun (Lond) 46 0037

PMID42368972
PMCIDPMC13305025
DOI10.34133/cancomm.0037
发表日期2026-06-29
入排依据:Randomized phase III breast cancer trial of a drug intervention, but its primary efficacy endpoint is ORR rather than a required time-to-event endpoint; thus it does not meet the cohort's time-to-event criterion.
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
入排复审未纳入:Randomized phase III breast cancer trial of a drug intervention, but its primary efficacy endpoint is ORR rather than a required time-to-event endpoint; thus it does not meet the cohort's time-to-event criterion.
摘要

摘要

Background: SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer. Methods: Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer were randomly assigned to receive SYHX2011 (260 mg/m2) or PAB (260 mg/m2) intravenously once every 3 weeks, stratified by prior taxane use and rash history (prior taxane with rash, prior taxane without rash, or no prior taxane), as well prior lines of chemotherapy for advanced disease (0 or ≥1). The primary endpoint was objective response rate assessed by an independent review committee. Noninferiority was to be declared if the lower bound of the 95% confidence interval (CI) for the rate ratio exceeded 0.75; if the lower bound exceeded 1, superiority would subsequently be tested and considered confirmed. Results: In this multicenter, randomized, double-blind, phase III trial across 56 centers in China, 621 patients were screened between 2023 April 23 and 2024 March 21, of whom 459 patients were randomized to SYHX2011 (n = 229) or PAB (n = 230). The confirmed objective response rate assessed by an independent review committee was 35.8% (95% CI 29.4% to 42.6%) for SYHX2011 and 25.8% (95% CI 20.2% to 32.1%) for PAB (rate ratio = 1.38, 95% CI 1.04 to 1.84; one-sided P = 0.012), indicating that SYHX2011 was noninferior to PAB. The superiority of SYHX2011 over PAB was also confirmed. SYHX2011 showed a lower incidence of rash compared with PAB during the first 2 administration cycles (13.6% vs. 34.3%) and all treatment cycles (16.2% vs. 42.6%). Treatment-related adverse events (TRAEs) occurred in 98.2% of patients receiving SYHX2011 and 98.3% of patients receiving PAB. In the SYHX2011 group, 111 (48.7%) patients experienced grade ≥3 TRAEs, compared with 101 (43.9%) patients in the PAB group. The most common grade ≥3 TRAEs were neutropenia, leukopenia, and peripheral sensory neuropathy. The median investigational drug reconstitution time was 2.0 min for SYHX2011 and 11.0 min for PAB. Conclusions: SYHX2011 demonstrated greater therapeutic benefits than PAB and significantly reduced the incidence of rash. Additionally, it could offer greater convenience in clinical application, providing advanced breast cancer patients with more effective and safer treatment options. Trial registration: ClinicalTrials.gov identifier: NCT05753865. Date of registration: 2023 February 22.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 2.

Kaplan–Meier estimates of survival in the ITT population. (A) Progression-free survival. (B) Time to progression. (C) Overall survival. CI, confidence interval; HR, hazard ratio; ITT, intention to treat; NR, not reached; OS, overall survival; PFS, progression-free survival; TTP, time to progression.

A

Progression-free survival (PFS)

Fig. 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Time to progression (TTP)

Fig. 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall survival (OS)

Fig. 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Study profile. At the cutoff date of 2024 September 21, 459 patients were enrolled. a One patient did not receive SYHX2011 after randomization. ITT, intention to treat; mITT, modified intention to treat; SS, safety analysis set.
非 KM Figure
Fig. 3.Incidence of rash in the SYHX2011 and PAB groups during the first 2 administration cycles and all treatment cycles. CI, confidence interval; PAB, paclitaxel for injection (albumin-bound); RR, rate ratio.
非 KM Figure